CXCL16 and Hepatic fibrosis: Thus, CX3CR1 limits liver fibrosis in vivo by regulating the differentiation and survival of intrahepatic monocytes (64).Studies have also shown that administration of CX3CR1 agonists (such as CXCL16 analogs) can reduce Kupffer cell activation, decrease TNF-α/IL-6 levels, and ameliorate steatohepatitis in high-fat diet mouse models (65).In our study, through single-cell analysis, we discovered CX3CR1 predominantly enriched in neutrophils and innate lymphoid cells.